Tango Therapeutics TNGX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Business | ||||||
| Discovery Direct Program Expenses-RD | $1.87M+46.6% | $1.28M-15.0% | $1.5M-44.5% | $2.71M-42.1% | $4.68M+3.6% | |
| Facilities And Other Related Expenses-RD | $4.34M-7.2% | $4.67M-4.6% | $4.9M-9.7% | $5.43M-0.7% | $5.47M+53.9% | |
| Personnel-Related Expenses-RD | $12.93M+4.2% | $12.41M+0.3% | $12.38M-3.6% | $12.83M-7.3% | $13.85M+5.3% | |
| TNG260Direct Program Expenses-RD | $2.01M+86.9% | $1.08M-35.4% | $1.66M-8.0% | $1.81M+4.6% | $1.73M+20.5% | |
| TNG456Direct Program Expenses-RD | $2.06M+29.8% | $1.59M-20.5% | $2M+21.4% | $1.65M+24.3% | $1.32M-70.8% | |
| TNG908Direct Program Expenses-RD | $581K-31.2% | $845K-31.5% | $1.23M-0.1% | $1.24M-27.9% | $1.71M-39.1% | |
| TNG961Direct Program Expenses-RD | $408K-49.8% | $813K-24.0% | $1.07M-31.9% | $1.57M-29.2% | $2.22M— | |
| Vopimetostat Direct Program Expenses-RD | $9.33M-0.9% | $9.41M+55.1% | $6.07M+8.8% | $5.58M+2.1% | $5.46M+36.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Tango Therapeutics break its business down?
- Tango Therapeutics (TNGX) reports research and development expense by business across 8 parts — Discovery Direct Program Expenses-RD, Facilities And Other Related Expenses-RD, Personnel-Related Expenses-RD, TNG260Direct Program Expenses-RD and TNG456Direct Program Expenses-RD. Each is extracted from the segment footnotes and tracked over time.
- Where does Tango Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Tango Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.